Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Victor Cassella who wrote (646)	11/10/1997 1:18:00 PM
From: Kip518	Read Replies (2) \| Respond to of 1605

This explains some of the action today: Oscar Gruss & Son Inc./Gargiulo Group Division Initiates Coverage with BUY on Vasomedical, Inc. NEW YORK--(BUSINESS WIRE)--Nov. 10, 1997--Oscar Gruss & Son Incorporated/Gargiulo Group Division initiates research coverage of Vasomedical, Inc., Westbury, NY, with a BUY recommendation. NASDAQ: (VASO) Alan Tuchman, M.D., equity analyst at the Gargiulo Group Division, believes the company's commercialization of EECP(R), a microprocessor-based medical device for the non-invasive, atraumatic treatment of patients with coronary artery disease may offer an alternative treatment to many heart disease patients. The company is currently focusing its efforts on one of its FDA-approved indications, the treatment of stable angina. Dr. Tuchman feels this new approach to angina and other cardiovascular problems makes EECP(R) an interesting, and potentially very remunerative, alternative to more invasive procedures. A multicenter, double-blind study of the use of EECP(R) is to be presented November 11, 1997, at the American Heart Association annual scientific sessions in Orlando, Florida. Dr. Tuchman gives details on Vasomedical, Inc., in a research report that can be obtained for a fee from the Gargiulo Group Division at (212) 952-1220. Investment Rating: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months....